BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure

Heart failure is a chronic clinical syndrome involving up to 6.5 million people in Europe. It is the leading cause of hospitalisation in adults, yielding a healthcare cost of 17 billion euro/year. The mortality rate is comparable/superior to several type of cancers in the EU perspective, reaching 70% at 5-year in the advanced stages of heart failure.

The BIOTOOL project seeks to revolutionise the treatment of heart failure with reduced ejection fraction (HF-REF) by offering a more efficient and personalised approach, through innovative tools and digital solutions, to manage diuretic therapy in heart failure with reduced ejection fraction, reduce heart failure hospitalisations and improve patients’ quality of life.

The objectives of BIOTOOL-CHF include the validation of qualified biomarkers estimating congestion, the definition of an artificial intelligence-based score predicting congestion and prognosis, the development of a decision-making tool for diuretic management, the creation of a Point of Care companion diagnostic (CD) for assessing biomarkers concentrations, and the establishment of a Strategy plan for industrial development and market access of the CD.

Consortium

El project is made up by a consortium of twenty-four hospitals, universities, and research centers from Italy, Germany, France, the Netherlands, Belgium, Greece, Slovenia, Spain, Denmark, Switzerland, and Sweden.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them